# A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

> **NCT03522649** · PHASE3 · UNKNOWN · sponsor: **1Globe Health Institute LLC** · enrollment: 668 (estimated)

## Conditions studied

- Previously Treated Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Napabucasin
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03522649
- **Lead sponsor:** 1Globe Health Institute LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-12
- **Primary completion:** 2021-11
- **Final completion:** 2021-11
- **Target enrollment:** 668 (ESTIMATED)
- **Last updated:** 2019-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03522649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03522649, "A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03522649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*